Andrew Combs Buys 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock

Prelude Therapeutics Incorporated (NASDAQ:PRLD) insider Andrew Combs bought 60,000 shares of the stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $1.37 per share, for a total transaction of $82,200.00. Following the acquisition, the insider now directly owns 377,623 shares of the company’s stock, valued at approximately $517,343.51. This represents a 18.89 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Andrew Combs also recently made the following trade(s):

• On Friday, December 20th, Andrew Combs purchased 3,075 shares of Prelude Therapeutics stock. The stock was bought at an average price of $1.15 per share, for a total transaction of $3,536.25.

Prelude Therapeutics Trading Down 4.3 %

PRLD opened at $1.34 on Friday. The stock has a 50-day moving average of $1.15 and a 200 day moving average of $3.08. Prelude Therapeutics Incorporated has a 12 month low of $0.80 and a 12 month high of $6.80. The firm has a market cap of $73.75 million, a P/E ratio of -0.75 and a beta of 1.49.

Prelude Therapeutics (NASDAQ:PRLD) last announced its earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. The company had revenue of $3.00 million during the quarter. On average, research analysts forecast that Prelude Therapeutics Incorporated will post -1.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Prelude Therapeutics by 86.0% in the 3rd quarter. Barclays PLC now owns 27,165 shares of the company’s stock worth $57,000 after acquiring an additional 12,564 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock worth $111,000 after purchasing an additional 14,769 shares during the period. XTX Topco Ltd bought a new stake in Prelude Therapeutics in the third quarter worth about $100,000. Exchange Traded Concepts LLC boosted its position in shares of Prelude Therapeutics by 32.2% during the third quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after buying an additional 15,682 shares during the period. Finally, Walleye Capital LLC grew its stake in shares of Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after buying an additional 67,946 shares during the last quarter. Institutional investors own 79.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PRLD shares. HC Wainwright reissued a “buy” rating and set a $5.00 price target on shares of Prelude Therapeutics in a research note on Friday, November 8th. JMP Securities reiterated a “market outperform” rating and set a $4.00 target price (down from $7.00) on shares of Prelude Therapeutics in a research report on Wednesday, December 11th.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.